Literature DB >> 7578522

Autologous platelet transfusion in alloimmunized patients with acute leukemia.

I Funke1, M Wiesneth, K Koerner, M Cardoso, E Seifried, B Kubanek, H Heimpel.   

Abstract

Seventy-eight transfusions of autologous platelets were given to eight alloimmunized patients receiving curative chemotherapy for acute leukemia. Platelets were collected at regeneration of hematopoiesis after a chemotherapy cycle, cryopreserved with 5% dimethylsulfoxide in liquid nitrogen, and retransfused during bone marrow aplasia following the next treatment cycle. The in vitro platelet recovery after freezing, thawing, and washing was 85 +/- 4%. The in vivo corrected count increment 1 h after autologous platelet transfusions was 11 +/- 5 x 10(9)/l. With the exception of moderate urticaria and slight nausea each after one transfusion, no immediate or chronic side effects occurred. The bleeding time was shortened and hemorrhage during bone marrow aplasia was prevented in all alloimmunized patients by autologous platelet transfusions.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7578522     DOI: 10.1007/BF01910313

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  27 in total

1.  The quantitative relation between platelet count and hemorrhage in patients with acute leukemia.

Authors:  L A GAYDOS; E J FREIREICH; N MANTEL
Journal:  N Engl J Med       Date:  1962-05-03       Impact factor: 91.245

2.  Comparison of plateletpheresis with two different cell separators using 100 identical donors.

Authors:  M Wiesneth; J Freudenberg; S Platow; J Kalinova; M Vogel; B Kubanek
Journal:  Beitr Infusionsther       Date:  1991

3.  Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial.

Authors:  M van Marwijk Kooy; H C van Prooijen; M Moes; I Bosma-Stants; J W Akkerman
Journal:  Blood       Date:  1991-01-01       Impact factor: 22.113

4.  Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia.

Authors:  J Gmür; J Burger; U Schanz; J Fehr; A Schaffner
Journal:  Lancet       Date:  1991-11-16       Impact factor: 79.321

5.  The predictive value of crossmatching platelet transfusion for alloimmunized patients.

Authors:  T S Kickler; H Braine; P M Ness
Journal:  Transfusion       Date:  1985 Jul-Aug       Impact factor: 3.157

6.  Frozen autologous platelet transfusion for patients with leukemia.

Authors:  C A Schiffer; J Aisner; P H Wiernik
Journal:  N Engl J Med       Date:  1978-07-06       Impact factor: 91.245

7.  Factors influencing the transfusion response to HLA-selected apheresis donor platelets in patients refractory to random platelet concentrates.

Authors:  J G McFarland; A J Anderson; S J Slichter
Journal:  Br J Haematol       Date:  1989-11       Impact factor: 6.998

8.  Serological studies in patients on platelet- and granulocyte-substitution therapy.

Authors:  J G Pegels; E C Bruynes; C P Engelriet; A E von dem Borne
Journal:  Br J Haematol       Date:  1982-09       Impact factor: 6.998

9.  Prevention of primary HLA class I allo-immunization with leucocyte-poor blood components produced without the use of platelet filters.

Authors:  M A Ten Haaft; P M Van den Berg-Loonen; D J Van Rhenen
Journal:  Vox Sang       Date:  1992       Impact factor: 2.144

10.  Clinical and blood bank factors in the management of platelet refractoriness and alloimmunization.

Authors:  R C Friedberg; S F Donnelly; J C Boyd; L S Gray; P D Mintz
Journal:  Blood       Date:  1993-06-15       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.